Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Rating) – Analysts at SVB Leerink issued their FY2024 EPS estimates for shares of Trevi Therapeutics in a report issued on Tuesday, November 22nd. SVB Leerink analyst T. Smith anticipates that the company will post earnings of ($0.59) per share for the year. SVB Leerink currently has a “Outperform” rating and a $6.00 price target on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.55) per share. SVB Leerink also issued estimates for Trevi Therapeutics’ FY2025 earnings at ($0.83) EPS.
TRVI has been the topic of a number of other reports. Needham & Company LLC cut their target price on shares of Trevi Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 11th. Oppenheimer lowered their target price on shares of Trevi Therapeutics to $9.00 in a research report on Thursday, November 17th.
Trevi Therapeutics Trading Down 2.7 %
Trevi Therapeutics (NASDAQ:TRVI – Get Rating) last issued its quarterly earnings results on Thursday, November 10th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.03.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp raised its stake in shares of Trevi Therapeutics by 93.4% during the 3rd quarter. State Street Corp now owns 77,042 shares of the company’s stock worth $119,000 after buying an additional 37,200 shares during the last quarter. Two Sigma Investments LP purchased a new stake in Trevi Therapeutics during the 3rd quarter worth about $122,000. Vanguard Group Inc. increased its position in Trevi Therapeutics by 459.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,324,377 shares of the company’s stock worth $2,040,000 after purchasing an additional 1,087,437 shares in the last quarter. Marshall Wace LLP purchased a new stake in Trevi Therapeutics during the 3rd quarter worth about $198,000. Finally, Armistice Capital LLC increased its position in Trevi Therapeutics by 107.7% during the 3rd quarter. Armistice Capital LLC now owns 864,000 shares of the company’s stock worth $1,331,000 after purchasing an additional 448,000 shares in the last quarter.
About Trevi Therapeutics
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.
- Get a free copy of the StockNews.com research report on Trevi Therapeutics (TRVI)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.